WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, March 17, 2005

Hide?	Set Name	Query	Hit Count
	DB=EPAB; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L9	WO-2004089189-A2.did.	1
☐	L8	WO-2004089189-A2.did.	1
	DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L7	Stanziale S .in.	1
	DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L6	US-20030228281-A1.did.	1
☐	L5	US-20030228281-A1.did.	1
☐	L4	US-20020071832-A1.did.	1
☐	L3	US-20020071832-A1.did.	1
	DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L2	L1 and oncolytic	3
☐	L1	fong Y.in.	34

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, March 17, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L36	L19 and VSV	36
☐	L35	Porosnicu M.in. and VSV	0
☐	L34	L9 and VSV	0
☐	L33	debensky T .in. and VSV	0
☐	L32	Dubensky T.in and L19	0
☐	L31	Geidlin M.in and l19	0
☐	L30	L19 and Atkins.in.	4
☐	L29	Watkin S.in. and L19	0
	DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L28	US-20030044386-A1.did.	1
☐	L27	US-20030044386-A1.did.	1
☐	L26	US-20030044386-A1.did.	1
	DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L25	L19 and barber G.in.	1
☐	L24	L19 and balachadran S.in.	0
☐	L23	Woo S.in. and L19	0
☐	L22	L19 and Whitt M.in.	1
☐	L21	L19 and Connor J.in.	0
☐	L20	L19 and Ahmed M.in.	0
☐	L19	oncolytic	758
☐	L18	L17 and oncolytic	0
☐	L17	Lyles D.in.	341
☐	L16	l14 and oncolysis	0
☐	L15	L14 and oncolytic	0
☐	L14	Ebert O.in.	3
☐	L13	l11 and oncolysis	0
☐	L12	L11 and oncolytic	0
☐	L11	shinozaki K.in.	124
☐	L10	L9 and oncolytic	0
☐	L9	Woo S.in.	1061
☐	L8	L6 and oncolysis	0

☐	L7	L6 and oncolytic	0
☐	L6	Baton .in.	20
☐	L5	Sinkovics J.in.	0
	DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L4	US-20030044386-A1.did.	1
☐	L3	US-20030044386-A1.did.	1
	DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L2	L1 and oncolytic	1
☐	L1	Barber G.in.	60

END OF SEARCH HISTORY

About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)
Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 20 of 21 Page 1 of 2

1: Barber GN. Related Articles,

Vesicular stomatitis virus as an oncolytic vector.
Viral Immunol. 2004;17(4):516-27. Review.
PMID: 15671748 [PubMed - indexed for MEDLINE]

2: Shinozaki K, Ebert O, Woo SL. Related Articles,

Eradication of advanced hepatocellular carcinoma in rats via repeated hepati arterial infusions of recombinant VSV.
Hepatology. 2005 Jan;41(1):196-203.
PMID: 15619242 [PubMed - indexed for MEDLINE]

3: Shinozaki K, Ebert O, Woo SL. Related Articles,

Treatment of multi-focal colorectal carcinoma metastatic to the liver of imm competent and syngeneic rats by hepatic artery infusion of oncolytic vesicul stomatitis virus.
Int J Cancer. 2005 Apr 20;114(4):659-64.
PMID: 15609320 [PubMed - in process]

4: Ebert O, Harbaran S, Shinozaki K, Woo SL. Related Articles,

Systemic therapy of experimental breast cancer metastases by mutant vesicu stomatitis virus in immune-competent mice.
Cancer Gene Ther. 2004 Nov 26; [Epub ahead of print]
PMID: 15565179 [PubMed - as supplied by publisher]

5: Ahmed M, Cramer SD, Lyles DS. Related Articles,

Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Virology. 2004 Dec 5;330(1):34-49.
PMID: 15527832 [PubMed - in process]

6: Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC. Related Articles,

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.
Hum Gene Ther. 2004 Sep;15(9):821-31.
PMID: 15353037 [PubMed - indexed for MEDLINE]

7: Connor JH, Naczki C, Koumenis C, Lyles DS. Related Articles,

Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo.

J Virol. 2004 Sep;78(17):8960-70.
PMID: 15308693 [PubMed - indexed for MEDLINE]

8: Duntsch CD, Zhou Q, Jayakar HR, Weimar JD, Robertson JH, Pfeffer LM, Wang L, Xiang Z, Whitt MA. Related Articles,

Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model.
J Neurosurg. 2004 Jun;100(6):1049-59.
PMID: 15200120 [PubMed - indexed for MEDLINE]

9: Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL. Related Articles,

Syncytia induction enhances the oncolytic potential of vesicular stomatitis vi in virotherapy for cancer.
Cancer Res. 2004 May 1;64(9):3265-70.
PMID: 15126368 [PubMed - indexed for MEDLINE]

10: Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. Related Articles,

Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
Mol Ther. 2004 Mar;9(3):368-76.
PMID: 15006603 [PubMed - indexed for MEDLINE]

11: Balachandran S, Barber GN. Related Articles,

Defective translational control facilitates vesicular stomatitis virus oncolysi
Cancer Cell. 2004 Jan;5(1):51-65.
PMID: 14749126 [PubMed - indexed for MEDLINE]

12: Porosnicu M, Mian A, Barber GN. Related Articles,

The oncolytic effect of recombinant vesicular stomatitis virus is enhanced b expression of the fusion cytosine deaminase/uracil phosphoribosyltransfera suicide gene.
Cancer Res. 2003 Dec 1;63(23):8366-76.
PMID: 14678998 [PubMed - indexed for MEDLINE]

13: Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA, Watkins SC. Related Articles,

Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressi breast cancer cells.
Virology. 2003 Nov 25;316(2):337-47.
PMID: 14644615 [PubMed - indexed for MEDLINE]

14: Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. Related Articles,

VSV strains with defects in their ability to shutdown innate immunity are p systemic anti-cancer agents.
Cancer Cell. 2003 Oct;4(4):263-75.
PMID: 14585354 [PubMed - indexed for MEDLINE]

15: Giedlin MA, Cook DN, Dubensky TW Jr. Related Articles,

Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus cand for cancer or just another chapter from Field's Virology?
Cancer Cell. 2003 Oct;4(4):241-3. Review.
PMID: 14585348 [PubMed - indexed for MEDLINE]

16: Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SL. Related Articles.

Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicu stomatitis virus in immune-competent mice.
Mol Ther. 2003 Sep;8(3):434-40.
PMID: 12946316 [PubMed - indexed for MEDLINE]

17: Obuchi M, Fernandez M, Barber GN. Related Articles.

Development of recombinant vesicular stomatitis viruses that exploit defec host defense to augment specific oncolytic activity.
J Virol. 2003 Aug;77(16):8843-56.
PMID: 12885903 [PubMed - indexed for MEDLINE]

18: Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SL. Related Articles.

Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellul carcinoma in immune-competent rats.
Cancer Res. 2003 Jul 1;63(13):3605-11.
PMID: 12839948 [PubMed - indexed for MEDLINE]

19: Fernandez M, Porosnicu M, Markovic D, Barber GN. Related Articles.

Genetically engineered vesicular stomatitis virus in gene therapy: applicati for treatment of malignant disease.
J Virol. 2002 Jan;76(2):895-904.
PMID: 11752178 [PubMed - indexed for MEDLINE]

20: Balachandran S, Porosnicu M, Barber GN. Related Articles.

Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis.
J Virol. 2001 Apr;75(7):3474-9.
PMID: 11238874 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 21 Page 1 of 2

Display Summary Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Mar 14 2005 07:08:36

Item 21 of 21 Previous Page 2

21: Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Related Articles,

Exploiting tumor-specific defects in the interferon pathway with a previous unknown oncolytic virus.
Nat Med. 2000 Jul;6(7):821-5.
PMID: 10888934 [PubMed - indexed for MEDLINE]

Item 21 of 21 Previous Page 2

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 6 of 6 One

1: Shinozaki K, Ebert O, Woo SL. Related Articles,

Treatment of multi-focal colorectal carcinoma metastatic to the liver of imm competent and syngeneic rats by hepatic artery infusion of oncolytic vesicul stomatitis virus.
Int J Cancer. 2005 Apr 20;114(4):659-64.
PMID: 15609320 [PubMed - in process]

2: Lichty BD, Power AT, Stojdl DF, Bell JC. Related Articles,

Vesicular stomatitis virus: re-inventing the bullet.
Trends Mol Med. 2004 May;10(5):210-6.
PMID: 15121047 [PubMed - in process]

3: Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. Related Articles,

Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic a infusion of vesicular stomatitis virus.
Mol Ther. 2004 Mar;9(3):368-76.
PMID: 15006603 [PubMed - indexed for MEDLINE]

4: Balachandran S, Barber GN. Related Articles,

Defective translational control facilitates vesicular stomatitis virus oncolysis
Cancer Cell. 2004 Jan;5(1):51-65.
PMID: 14749126 [PubMed - indexed for MEDLINE]

5: Porosnicu M, Mian A, Barber GN. Related Articles,

The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferas suicide gene.
Cancer Res. 2003 Dec 1;63(23):8366-76.
PMID: 14678998 [PubMed - indexed for MEDLINE]

6: Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SL. Related Articles,

Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicula stomatitis virus in immune-competent mice.
Mol Ther. 2003 Sep;8(3):434-40.
PMID: 12946316 [PubMed - indexed for MEDLINE]

1: Anticancer Res. 1989 Sep-Oct;9(5):1281-90. Related Articles

Oncogenes-antioncogenes and virus therapy of cancer.

Sinkovics JG.

Department of Medicine, University of South Florida College of Medicine, Tampa.

Viruses can render services to mankind. 1. Retroviruses pinpoint and transdu cellular oncogenes. 2. Retroviral vectors can introduce antioncogenes (the RI gene) into malignant cells thus rendering the recipient cells nonmalignant. 3. Oncolytic viruses lyse tumor cells. 4. Parvoviruses replicate only in dividing and exert lysis and antioncogene effect in tumor cells without affecting restir normal cells. 5. Myxo- and paramyxoviruses (and other viruses) upgrade the immunogenicity of cell surface antigens thus eliciting rejection type host immunity against these cells which is operational against not virus-infected c of the same type (post-oncolytic antitumor immunity). 6. Viruses or virally infected cells (including tumor cells) induce the production of lymphokines a cytokines (interferons, interleukins and tumor necrosis factor) and activate N cells and specific immune T cells cytotoxic to virus-infected cells (including tumor cells). 7. Measles virus may activate suppressor cells and both directly infecting lymphoma cells) and indirectly (by inducing molecular mediators o suppressor mononuclear cells inhibitory to the growth of neoplastic lymphoi hematopoietic cells) induce remissions of lympho- and hematopoietic malignancies. 8. Retroviral vectors deliver genes into tumor cells for encodin new surface antigens that render the tumor cells highly antigenic and more vulnerable to rejection type immune reactions of the host. Examples illustrat statement. Immunotherapy of tumors with active tumor-specific immunizatic after the induction of suppressor cells by fetal antigens and the elimination o proliferating suppressor clones by cyclophosphamide will again be proposed

Publication Types:
- Review

PMID: 2556069 [PubMed - indexed for MEDLINE]

1: Int Rev Immunol. 1991;7(4):259-87.

Viral oncolysates as human tumor vaccines.

Sinkovics JG.

Cancer Institute, St. Joseph's Hospital, Tampa, Florida.

Postoncolytic immunity entails immune reactions acquired through an oncol virus infection or through repeated immunizations with viral oncolysates (or virally modified tumor cell membranes) that are valid and operational also a virally not modified tumor cells of the same type. NK cells react to budding virions, induce target cell lysis primarily but not exclusively by the productic granzymes and pore-forming proteins and operate without direction from me cells. In contrast, immune T cells (including some TIL) are MHC-restricted, under the direction of memory cells and lyse target cells primarily but not exclusively by the release of lymphotoxin (TNF beta) causing programmed c death (apoptosis) through endonuclease activation and target cell DNA fragmentation. This author proposes that it is not NK, but the immune T cell mediate postoncolytic immunity. Oncogene amplification may protect immortalized tumor cells even when expressing peptide antigens through MH molecules against lymphotoxin-mediated apoptosis; but virally-infected tum cells releasing budding virions remain susceptible to NK cells. Highly immunogenic viral oncolysates should present both budding virions for NK c and processed viral and tumoral peptide antigens co-jointly for immune T cel

Publication Types:

- Review
- Review, Tutorial

PMID: 1663989 [PubMed - indexed for MEDLINE]